trending Market Intelligence /marketintelligence/en/news-insights/trending/m6veS9jwAXN1tFHWoxm4Jg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer's Indian manufacturing plant gets US FDA warning letter before shutdown

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Pfizer's Indian manufacturing plant gets US FDA warning letter before shutdown

The U.S. Food and Drug Administration issued a warning letter to Pfizer Inc.'s Indian manufacturing plant, which is about to be shut down, citing violations of product quality and data integrity issues.

In the March 4 letter, the U.S. regulator said the methods and facilities for manufacturing, processing and packing at Pfizer's manufacturing plant in Irungattukottai, in the state of Tamil Nadu, did not conform to Current Good Manufacturing Practice regulations.

Pfizer had voluntarily paused production at the sterile injectables plant in 2018 after an FDA inspection found issues at the site for the third time since 2013. The issues were related to the manipulation of data by workers was also cited by the FDA.

The FDA said in the warning letter that the New York-based pharmaceutical giants' response to several violations, which included manufacturing and data integrity, was inadequate.

In addition, the U.S. regulator noted that the drug products manufactured at the site were adulterated. The laboratory records did not include complete data derived from all tests, while critical data integrity breaches identified in the inspection raised concerns regarding the validity of all results reported by the quality control laboratory.

The FDA, however, noted that Pfizer had decided to recall all batches of a particular injection set from the U.S. market after testing showed unsatisfactory results.

Earlier in January, Pfizer confirmed its plans to shut down the Irungattukottai plant, which employs about 1,000 people and another facility in Aurangabad in the Indian state of Maharashtra, which employs about 700 people. The company said the decision was taken because manufacturing at these sites was not viable due to significant long-term loss of product demand.

The FDA added in its letter that rectifying the observations will be necessary if Pfizer or an acquirer resumes drug manufacturing at the Irungattukottai facility for the U.S. market.